MEDX Horizon Kinetics Medical ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · Eli Lilly and Company
Eli Lilly and Company cut by 5%
Shares went from 3,077 to 2,936 ($2.83M → $3.52M). Now 18.1% of the portfolio. Estimated trade $169K.
Largest holding: Eli Lilly and Company, cut 5%, 2,936 shares ($3.52M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $3.52M · −5% sh | 18.1% |
| US BANK MMDA - USBGFS 7 USBGFS7 $1.75M · −4% units | 9.0% |
| AbbVie Inc. ABBV $1.69M · −5% sh | 8.7% |
| Novartis AG NVS $1.31M · −5% sh | 6.8% |
| Johnson & Johnson JNJ $1.07M · −5% sh | 5.5% |
| Alkermes plc ALKS $1.05M · −5% sh | 5.4% |
| AstraZeneca AZN $951K · −5% sh | 4.9% |
| Ionis Pharmaceuticals, Inc. IONS $865K · −5% sh | 4.5% |
| Bristol-Myers Squibb Company BMY $844K · −5% sh | 4.3% |
| Merck & Company, Inc. MRK $755K · −5% sh | 3.9% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 89.6% |
| Consumer Defensive | 0.6% |
| Unclassified | 9.8% |
| Industries | % of holdings value |
|---|---|
| Drug Manufacturers - General | 57.9% |
| Biotechnology | 31.3% |
| Household & Personal Products | 0.6% |
| Medical Devices | 0.4% |
| Unclassified | 9.8% |
| Initiations 0 | Value |
|---|---|
| None this period. | |
| Increases 0 | Change |
|---|---|
| None this period. | |
| Reductions 30 | Change |
|---|---|
| Eli Lilly and Company LLY $2.83M → $3.52M | −5% |
| AbbVie Inc. ABBV $1.53M → $1.69M | −5% |
| Novartis AG NVS $1.34M → $1.31M | −5% |
| Johnson & Johnson JNJ $1.08M → $1.07M | −5% |
| Alkermes plc ALKS $746K → $1.05M | −5% |
| AstraZeneca AZN $1.04M → $951K | −5% |
| Ionis Pharmaceuticals, Inc. IONS $858K → $865K | −5% |
| Bristol-Myers Squibb Company BMY $931K → $844K | −5% |
| Merck & Company, Inc. MRK $740K → $755K | −5% |
| Amgen Inc. AMGN $760K → $747K | −5% |
| Alnylam Pharmaceuticals, Inc. ALNY $752K → $653K | −5% |
| Biogen Inc. BIIB $524K → $589K | −5% |
| Terminations 0 | Change |
|---|---|
| None this period. | |
The other 18 reductions
Pfizer, Inc. (−5%), GSK plc (−5%), CRISPR Therapeutics AG (−5%), Regeneron Pharmaceuticals, Inc. (−5%), Beam Therapeutics Inc. (−5%), Galectin Therapeutics Inc. (−5%), Intellia Therapeutics, Inc. (−5%), Sandoz Group AG (−5%), Replimune Group, Inc. (−5%), Vanda Pharmaceuticals Inc. (−5%), Haleon PLC (−5%), Lantern Pharma Inc. (−5%), Editas Medicine, Inc. (−5%), Bicycle Therapeutics plc (−5%), GE HealthCare Technologies Inc. (−5%), Viatris Inc. (−5%), Allogene Therapeutics, Inc. (−5%), Pacific Biosciences of California, Inc. (−5%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Apr 30, 2026.
Horizon Kinetics Medical ETF ("Medical ETF" or the "Fund") seeks to provide long-term growth of capital.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks (such as American Depositary Receipts ("ADRs"), Global Depositary Receipts ("GDRs") and International Depositary Receipts ("IDRs")) of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development, such as pharmaceutical development companies, surgical and medical instrument manufacturers and developers, pharmaceutical manufacturers, and biotech and medical research companies. These types of companies derive at least 50% of their revenue from such activities. The Fund also may invest in other ETFs and purchase and write options for hedging purposes and/or direct investment. In addition, the Fund may purchase or engage in short sales of certain leveraged or inverse ETFs. The Fund may invest up to 20% of its total assets in convertible and non-convertible debt securities rated below investment grade, also known as junk bonds, or unrated securities that Horizon Kinetics Asset Management LLC, the Fund's investment adviser (the "Adviser"), has determined to be of comparable quality. 2 The Adviser selects portfolio securities by evaluating a company's positioning and the resources that it currently expends on research and development, looking for a significant percentage, or large amount, of capital invested into research and treatment of cancer and other diseases. The Adviser also considers a company's fundamentals by reviewing its balance sheets, corporate revenues, earnings and dividends. The Adviser also considers at the amount of capital a company spends on research and development because the Adviser believes that such expenditures frequently have significant bearing on future growth. The Fund may invest in companies of any size, including small and medium-size companies. Additionally, the Fund may participate in securities lending arrangements up to 33 1/3% of the securities in its portfolio with brokers, dealers, and financial institutions (but not individuals) to seek to increase the return on its portfolio. Decisions to sell the Fund's portfolio holdings are generally triggered by either adequate value being achieved, as determined by the Adviser, or an adverse change in a company's operating performance or a deterioration of the company's business model. A sell trigger also may occur if the Adviser discovers a new investment opportunity that it believes is more compelling and represents a greater risk reward profile than other investment(s) held by the Fund. The Fund may maintain during a temporary period of abnormal conditions, a significant portion of its total assets in cash and securities, generally considered to be cash and cash equivalents, including, but not limited to: high quality, U.S. short-term debt securities and money market instruments. The Adviser will invest in such short-term cash positions to the extent the Adviser is unable to find sufficient investments meeting its criteria and when the Adviser believes the purchase of additional equity securities would not further the investment objective of the Fund during such periods of time. Additionally, to respond to adverse market, economic, political or other conditions, which may persist for short or long periods of time, the Fund may invest up to 100% of its assets in the types of high quality, U.S. short-term debt securities and money market instruments described above.
Management and Contact
- Adviser
- Horizon Kinetics Asset Management, LLC
- Portfolio managers
-
Peter B. Doyle, Co-Founder and Co-Chief Executive Officer, has been a portfolio manager of the Fund since January 2023 and was a Portfolio Manager of the Predecessor Fund since its inception in September 1999 through the Reorganization Date.
Steven Tuen, Portfolio Manager, James Davolos, Portfolio Manager, and Brandon Colavita, Portfolio Manager, have been portfolio managers of the Fund since April 2026.
- Phone
- 1-800-617-0004
- [email protected]
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | 5 Years | 10 Years | Since Inception | |
|---|---|---|---|---|
| Return Before Taxes | 28.45% | 5.80% | 5.67% | 8.47% |
| Return After Taxes on Distributions | 28.08% | 5.23% | 4.53% | 7.70% |
| Return After Taxes on Distributions and Sale of Shares | 17.11% | 4.46% | 4.24% | 7.20% |
| S&P 500® TR Index (reflects no deduction for fees, expenses, or taxes) | 17.88% | 14.42% | 14.82% | 8.57% |
| S&P 500® TR Index(reflects no deduction for fees, expenses, or taxes) | 17.88% | 14.42% | 14.82% | 8.57% |
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 26, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
33 lines, 30 linked, weights sum to 101.83% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY US5324571083 | Equity | 2,936 | −141 | 18.46% | $ 3.522M |
|
US BANK MMDA - USBGFS 7
|
USBGFS7 | Money market | 1,752,681.13 | −68,123.34 | 9.19% | $ 1.753M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 6,712 | −322 | 8.85% | $ 1.689M |
| Novartis AG | NVS US66987V1098 | Equity | 8,388 | −403 | 6.89% | $ 1.315M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 4,200 | −201 | 5.59% | $ 1.067M |
| Alkermes PLC | ALKS IE00B56GVS15 | Equity | 20,132 | −967 | 5.53% | $ 1.055M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 5,015 | −241 | 4.98% | $ 950.944K |
| Ionis Pharmaceuticals Inc | IONS US4622221004 | Equity | 10,904 | −524 | 4.53% | $ 864.578K |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 14,644 | −704 | 4.42% | $ 843.787K |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 5,872 | −282 | 3.96% | $ 754.552K |
| Amgen Inc | AMGN US0311621009 | Equity | 2,062 | −99 | 3.91% | $ 746.691K |
| Alnylam Pharmaceuticals Inc | ALNY US02043Q1076 | Equity | 2,168 | −104 | 3.42% | $ 652.633K |
| Biogen Inc | BIIB US09062X1037 | Equity | 2,726 | −131 | 3.09% | $ 588.98K |
| Pfizer Inc | PFE US7170811035 | Equity | 22,648 | −1,088 | 2.86% | $ 545.364K |
| GSK PLC | GSK US37733W2044 | Equity | 9,846 | −473 | 2.71% | $ 516.127K |
| CRISPR Therapeutics AG | CRSP CH0334081137 | Equity | 9,228 | −443 | 2.64% | $ 503.295K |
| Regeneron Pharmaceuticals Inc | REGN US75886F1075 | Equity | 630 | −30 | 2.06% | $ 392.83K |
| Beam Therapeutics Inc | BEAM US07373V1052 | Equity | 8,388 | −403 | 1.51% | $ 287.876K |
| Galectin Therapeutics Inc | GALT US3632252025 | Equity | 46,968 | −2,258 | 1.14% | $ 217.932K |
| Intellia Therapeutics Inc | NTLA US45826J1051 | Equity | 12,584 | −604 | 1.12% | $ 212.921K |
|
Sandoz Group AG
|
SDZNY US7999261008 | Equity | 1,680 | −80 | 0.80% | $ 152.023K |
| Replimune Group Inc | REPL US76029N1063 | Equity | 12,584 | −604 | 0.73% | $ 139.305K |
| Vanda Pharmaceuticals Inc | VNDA US9216591084 | Equity | 22,648 | −1,088 | 0.73% | $ 138.606K |
| Haleon PLC | HLN US4055521003 | Equity | 12,309 | −591 | 0.60% | $ 114.843K |
| Lantern Pharma Inc | LTRN US51654W1018 | Equity | 25,164 | −1,209 | 0.55% | $ 104.934K |
| Editas Medicine Inc | EDIT US28106W1036 | Equity | 27,680 | −1,330 | 0.47% | $ 89.683K |
| GE HealthCare Technologies Inc | GEHC US36266G1076 | Equity | 840 | −40 | 0.28% | $ 53.768K |
| Bicycle Therapeutics PLC | BCYC US0887861088 | Equity | 12,584 | −604 | 0.28% | $ 53.356K |
| Viatris Inc | VTRS US92556V1061 | Equity | 3,122 | −150 | 0.26% | $ 49.577K |
| Allogene Therapeutics Inc | ALLO US0197701065 | Equity | 16,776 | −806 | 0.18% | $ 34.894K |
| Pacific Biosciences of Califor | PACB US69404D1081 | Equity | 10,068 | −483 | 0.09% | $ 16.914K |
| Decoy Therapeutics Inc | DCOY US79400X6022 | Equity | 20.75 | 0 | 0.00% | $ 149.19 |
|
Pathos AI Inc
|
2368714D | Equity | 23,992 | 0 | 0.00% | $ 0.00 |
Trades Mar 31, 2026 to Jun 30, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY | Sold | 3,077 | 2,936 | −141 | $ -169.12K |
| AbbVie Inc | ABBV | Sold | 7,034 | 6,712 | −322 | $ -81.028K |
| Novartis AG | NVS | Sold | 8,791 | 8,388 | −403 | $ -63.158K |
| Johnson & Johnson | JNJ | Sold | 4,401 | 4,200 | −201 | $ -51.048K |
| Alkermes PLC | ALKS | Sold | 21,099 | 20,132 | −967 | $ -50.666K |
| AstraZeneca PLC | AZN | Sold | 5,256 | 5,015 | −241 | $ -45.698K |
| Ionis Pharmaceuticals Inc | IONS | Sold | 11,428 | 10,904 | −524 | $ -41.548K |
| Bristol-Myers Squibb Co | BMY | Sold | 15,348 | 14,644 | −704 | $ -40.564K |
| Merck & Co Inc | MRK | Sold | 6,154 | 5,872 | −282 | $ -36.237K |
| Amgen Inc | AMGN | Sold | 2,161 | 2,062 | −99 | $ -35.85K |
| Alnylam Pharmaceuticals Inc | ALNY | Sold | 2,272 | 2,168 | −104 | $ -31.307K |
| Biogen Inc | BIIB | Sold | 2,857 | 2,726 | −131 | $ -28.304K |
| Pfizer Inc | PFE | Sold | 23,736 | 22,648 | −1,088 | $ -26.199K |
| GSK PLC | GSK | Sold | 10,319 | 9,846 | −473 | $ -24.795K |
| CRISPR Therapeutics AG | CRSP | Sold | 9,671 | 9,228 | −443 | $ -24.161K |
| Regeneron Pharmaceuticals Inc | REGN | Sold | 660 | 630 | −30 | $ -18.706K |
| Beam Therapeutics Inc | BEAM | Sold | 8,791 | 8,388 | −403 | $ -13.831K |
| Galectin Therapeutics Inc | GALT | Sold | 49,226 | 46,968 | −2,258 | $ -10.477K |
| Intellia Therapeutics Inc | NTLA | Sold | 13,188 | 12,584 | −604 | $ -10.22K |
|
Sandoz Group AG
|
SDZNY | Sold | 1,760 | 1,680 | −80 | $ -7,239.20 |
| Replimune Group Inc | REPL | Sold | 13,188 | 12,584 | −604 | $ -6,686.28 |
| Vanda Pharmaceuticals Inc | VNDA | Sold | 23,736 | 22,648 | −1,088 | $ -6,658.56 |
| Haleon PLC | HLN | Sold | 12,900 | 12,309 | −591 | $ -5,514.03 |
| Lantern Pharma Inc | LTRN | Sold | 26,373 | 25,164 | −1,209 | $ -5,041.53 |
| Editas Medicine Inc | EDIT | Sold | 29,010 | 27,680 | −1,330 | $ -4,309.20 |
| Bicycle Therapeutics PLC | BCYC | Sold | 13,188 | 12,584 | −604 | $ -2,560.96 |
| GE HealthCare Technologies Inc | GEHC | Sold | 880 | 840 | −40 | $ -2,560.40 |
| Viatris Inc | VTRS | Sold | 3,272 | 3,122 | −150 | $ -2,382.00 |
| Allogene Therapeutics Inc | ALLO | Sold | 17,582 | 16,776 | −806 | $ -1,676.48 |
| Pacific Biosciences of Califor | PACB | Sold | 10,551 | 10,068 | −483 | $ -811.44 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up